[A case of the successful treatment of the esophageal leukoplakia with rabeprazole].
This clinical endoscopic study is of interest because clinical and endoscopic remission of the disease with a torpid course was achieved in a patient with gastroesophageal reflux disease with a continuously recurrent course complicated with leukoplakia under the condition of regular combination of preparations of the base course PPIs (Pariet) + prokinetic agent (Motilium) + antacid (Magalphil), conduction of continuous treatment during 12 weeks and subsequent supporting therapy (Pariet, 20 mg) during 6 months in the weekend treatment mode, as well as adherence to recommendations for changing the lifestyle.
Arutiunov
A G
AG
Burkov
S G
SG
Burdina
E G
EG
Svirchev
V V
VV
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000368:Aged; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D004942:Esophagitis, Peptic / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007971:Leukoplakia / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives; D054328:Proton Pump Inhibitors; D064750:Rabeprazole
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D009853:Omeprazole